MX385788B - Método de tratamiento con tradipitant. - Google Patents

Método de tratamiento con tradipitant.

Info

Publication number
MX385788B
MX385788B MX2017011279A MX2017011279A MX385788B MX 385788 B MX385788 B MX 385788B MX 2017011279 A MX2017011279 A MX 2017011279A MX 2017011279 A MX2017011279 A MX 2017011279A MX 385788 B MX385788 B MX 385788B
Authority
MX
Mexico
Prior art keywords
treatment method
tradipitant
tradipitant treatment
treatment
pruritus
Prior art date
Application number
MX2017011279A
Other languages
English (en)
Spanish (es)
Other versions
MX2017011279A (es
Inventor
Louis William Licamele
Mihael H Polymeropoulos
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of MX2017011279A publication Critical patent/MX2017011279A/es
Publication of MX385788B publication Critical patent/MX385788B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Encapsulation Of And Coatings For Semiconductor Or Solid State Devices (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Steroid Compounds (AREA)
  • Eye Examination Apparatus (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2017011279A 2015-03-04 2016-03-04 Método de tratamiento con tradipitant. MX385788B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562128472P 2015-03-04 2015-03-04
US201562232644P 2015-09-25 2015-09-25
PCT/US2016/021015 WO2016141341A1 (en) 2015-03-04 2016-03-04 Method of treatment with tradipitant

Publications (2)

Publication Number Publication Date
MX2017011279A MX2017011279A (es) 2018-01-25
MX385788B true MX385788B (es) 2025-03-18

Family

ID=55629110

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017011279A MX385788B (es) 2015-03-04 2016-03-04 Método de tratamiento con tradipitant.
MX2021010460A MX2021010460A (es) 2015-03-04 2017-09-04 Metodo de tratamiento con tradipitant.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021010460A MX2021010460A (es) 2015-03-04 2017-09-04 Metodo de tratamiento con tradipitant.

Country Status (19)

Country Link
US (6) US10463655B2 (enExample)
EP (2) EP3265087B1 (enExample)
JP (4) JP6891385B2 (enExample)
KR (3) KR102860817B1 (enExample)
CN (2) CN113262221A (enExample)
AU (4) AU2016226006B2 (enExample)
BR (1) BR112017018620A2 (enExample)
CA (2) CA3213864A1 (enExample)
CL (1) CL2017002238A1 (enExample)
DK (1) DK3265087T3 (enExample)
ES (1) ES2824552T3 (enExample)
HR (1) HRP20201627T1 (enExample)
HU (1) HUE050944T2 (enExample)
IL (1) IL254142B (enExample)
MX (2) MX385788B (enExample)
PT (1) PT3265087T (enExample)
RU (1) RU2770050C2 (enExample)
WO (1) WO2016141341A1 (enExample)
ZA (1) ZA201706059B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102860817B1 (ko) * 2015-03-04 2025-09-16 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피턴트에 의한 치료 방법
CN111093671A (zh) * 2017-09-13 2020-05-01 万达制药公司 以托吡坦对特应性皮炎的改进治疗
ES3032138T3 (en) * 2017-11-17 2025-07-15 Vanda Pharmaceuticals Inc Tradipitant for use in treating gastroparesis
CA3101210A1 (en) * 2018-06-08 2019-12-12 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
JP7468964B2 (ja) * 2018-09-28 2024-04-16 バンダ・ファーマシューティカルズ・インコーポレイテッド 動揺病におけるトラジピタントの使用
US20220096449A1 (en) * 2018-12-03 2022-03-31 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
WO2020132513A1 (en) 2018-12-21 2020-06-25 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
CN115052599A (zh) * 2020-02-25 2022-09-13 万达制药公司 以川地匹坦对特应性皮炎的改进治疗
US20230145932A1 (en) * 2020-03-26 2023-05-11 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
KR20250123807A (ko) 2022-12-21 2025-08-18 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피탄트를 이용한 치료 방법
US20250255855A1 (en) 2024-02-09 2025-08-14 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9305718D0 (en) 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
TW263498B (enExample) * 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
GB9513972D0 (en) 1995-07-08 1995-09-06 Merck Sharp & Dohme Pharmaceutical compositions
ES2226622T3 (es) 1999-02-24 2005-04-01 F. Hoffmann-La Roche Ag Derivados de 4-fenil piridina y su empleo como antagonistas del receptor nk-1.
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
MXPA04010622A (es) * 2002-04-26 2005-01-25 Lilly Co Eli Derivados de triazol como antagonistas de receptor de taquicinina.
DK1501808T3 (da) * 2002-04-26 2008-10-13 Lilly Co Eli Tachykininreceptor-antagonister
JP2004250329A (ja) 2002-12-26 2004-09-09 Dainippon Pharmaceut Co Ltd イサチン誘導体
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
BRPI0415010B8 (pt) * 2003-10-24 2021-05-25 Lilly Co Eli formas cristalinas iv e v de {2-[1-(3,5-bis-trifluorometilbenzil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il)-(2-clorofenil)-metanona, (2-clorofenil)-[2-(2-hidróxi-2-piridin-4-il-vinil)piridin-3-il]metanona, seus processos de preparação, e composição farmacêutica sólida
JP4673068B2 (ja) 2005-01-19 2011-04-20 独立行政法人科学技術振興機構 Th1型アレルギー疾患治療用組成物
DE102005006217B4 (de) 2005-02-07 2007-08-16 Universitätsklinikum Hamburg-Eppendorf Diagnose von allergischen Erkrankungen und/oder atopischen Erkrankungen durch Nachweis von Autoantikörpern gegen CD28 in humanem Serum
CA2643130A1 (en) 2006-02-22 2007-08-30 Valorisation Recherche Hscm, Limited Partnership Compounds and methods of treating disorders associated with activation of metachromatic cells
JP5443168B2 (ja) * 2006-12-20 2014-03-19 イーライ リリー アンド カンパニー {2−[1−(3,5−ビス−トリフルオロメチル−ベンジル)−5−ピリジン−4−イル−1h−[1,2,3]トリアゾール−4−イル]−ピリジン−3−イル}−(2−クロロフェニル)−メタノンの調製において有用な新規の中間体及び方法
CN105503870A (zh) 2009-08-14 2016-04-20 欧科生医股份有限公司 神经激肽-1拮抗剂的静脉内制剂
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
RS53491B1 (sr) 2009-11-18 2015-02-27 Helsinn Healthcare Sa Kompozicije za lečenje centralno posredovane mučnine i povraćanja
EP2931253A1 (en) 2012-12-13 2015-10-21 Heron Therapeutics, Inc. Pharmaceutical composition comprising antiemetic compounds and polyorthoester
JP6644328B2 (ja) 2013-02-28 2020-02-12 ロート製薬株式会社 アトピー性疾患の発症又は重症化リスクの評価法
US8906951B1 (en) * 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
EP3013336A1 (en) * 2013-06-24 2016-05-04 Tigercat Pharma Inc. Use of nk-1 receptor antagonist serlopitant in pruritus
KR102860817B1 (ko) * 2015-03-04 2025-09-16 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피턴트에 의한 치료 방법
WO2016195723A1 (en) 2015-06-03 2016-12-08 Beller Pharmaceuticals LLC Methods of treatment for conditions mediated by substance p
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
RU2724053C2 (ru) 2015-11-30 2020-06-19 Анакор Фармасьютикалз, Инк. Фармацевтические составы для местного применения для лечения связанных с воспалением состояний
CN115531553A (zh) 2015-12-22 2022-12-30 武田药品工业株式会社 内体g蛋白-偶联的受体的三部分调节剂
CN111093671A (zh) * 2017-09-13 2020-05-01 万达制药公司 以托吡坦对特应性皮炎的改进治疗
ES3032138T3 (en) * 2017-11-17 2025-07-15 Vanda Pharmaceuticals Inc Tradipitant for use in treating gastroparesis
CA3101210A1 (en) * 2018-06-08 2019-12-12 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
JP7468964B2 (ja) * 2018-09-28 2024-04-16 バンダ・ファーマシューティカルズ・インコーポレイテッド 動揺病におけるトラジピタントの使用
US20220096449A1 (en) * 2018-12-03 2022-03-31 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant

Also Published As

Publication number Publication date
JP2021073258A (ja) 2021-05-13
CN107427502B (zh) 2021-06-04
JP6891385B2 (ja) 2021-06-18
JP2024074963A (ja) 2024-05-31
CL2017002238A1 (es) 2018-04-20
US10463655B2 (en) 2019-11-05
ES2824552T3 (es) 2021-05-12
RU2770050C2 (ru) 2022-04-14
US20190290626A1 (en) 2019-09-26
DK3265087T3 (da) 2020-10-19
IL254142B (en) 2022-05-01
AU2025210905A1 (en) 2025-08-21
CA2978736C (en) 2023-11-07
KR20170122777A (ko) 2017-11-06
CA2978736A1 (en) 2016-09-09
MX2021010460A (es) 2021-09-21
JP2023052486A (ja) 2023-04-11
EP3265087B1 (en) 2020-07-22
HRP20201627T1 (hr) 2021-02-19
CN113262221A (zh) 2021-08-17
AU2023233141A1 (en) 2023-10-12
CA3213864A1 (en) 2016-09-09
ZA201706059B (en) 2023-08-30
US11324735B2 (en) 2022-05-10
KR20230173743A (ko) 2023-12-27
US20250205213A1 (en) 2025-06-26
JP2018507243A (ja) 2018-03-15
US10772880B2 (en) 2020-09-15
CN107427502A (zh) 2017-12-01
US20180110761A1 (en) 2018-04-26
HUE050944T2 (hu) 2021-01-28
RU2017134443A3 (enExample) 2019-09-05
PT3265087T (pt) 2020-10-15
IL254142A0 (en) 2017-10-31
US20200360358A1 (en) 2020-11-19
KR102860817B1 (ko) 2025-09-16
US20220226295A1 (en) 2022-07-21
US12318375B2 (en) 2025-06-03
AU2016226006A1 (en) 2017-09-21
WO2016141341A1 (en) 2016-09-09
AU2023233141B2 (en) 2025-05-22
BR112017018620A2 (pt) 2018-04-17
AU2016226006B2 (en) 2021-03-04
US20190290625A1 (en) 2019-09-26
KR20250136946A (ko) 2025-09-16
EP3265087A1 (en) 2018-01-10
RU2017134443A (ru) 2019-04-04
MX2017011279A (es) 2018-01-25
AU2021202956A1 (en) 2021-06-03
NZ735121A (en) 2024-07-26
EP3730140A1 (en) 2020-10-28
HK1248552A1 (zh) 2018-10-19
AU2021202956B2 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
MX2021010460A (es) Metodo de tratamiento con tradipitant.
EA201691991A1 (ru) Мультиспецифические антитела
MX377710B (es) Anticuerpos monoclonales contra bcma.
MX2020009461A (es) Anticuerpos anti-proteína que contiene dominio de inmunologlubina rfig elacionado con el receptor de poliovirus (pvrig) y métodos de uso.
EA201792613A1 (ru) Модуляторы cot и способы их применения
PH12017500019A1 (en) Novel ultra-high performance concrete
CA3058415C (en) Composition for producing tagatose and method of producing tagatose using the same
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
EA201600026A1 (ru) Бактериальная гиалуронидаза и способ ее производства
MY190747A (en) Method for producing silazane-siloxane copolymers and the use of such copolymers
PL3250042T3 (pl) Kompozycja, sposób, zastosowanie i wyrób
BR112016027455A2 (pt) moduladores ppar
EA201792527A1 (ru) Лечение зуда
MX2023009431A (es) Metodo para crear un compuesto a base de mercurio, compuesto a base de mercurio, metodos de uso del compuesto a base de mercurio y usos del compuesto a base de mercurio.
EP3463579A4 (en) CALLYSPONGIOLID, ANALOGUE FROM IT AND USES THEREOF
EA201792578A1 (ru) Многослойная сборка
LT3493849T (lt) N,n-bis-2-merkaptoetilizoftalamido naujas panaudojimas
RU2014119029A (ru) Способ остеопластической торакопластики из минидоступа
TN2014000384A1 (fr) نظام صوتي ذكي وآمن
TN2014000468A1 (fr) اختراع الة للف شباك مراكب الصيد البحري و تسهيل تحويلها من المركب الى رصيف الميناء ثم ارجاعها للمركب بعد القيام بعملية ترقيعها
TN2014000355A1 (fr) طريقة مبتكرة لتوفير الاضاءة العامة و المنزلية
UA114708U (uk) Тяговий привід електробуса
TN2014000377A1 (fr) طائرة كهربائية كاتمة للصوت
TN2014000522A1 (fr) لوح مدرسي بوجهين
UA97245U (en) Succinic acid application to strengthen the antihypoxic effect of thiotriazoline and quercetin